Previous studies have demonstrated that histone deacetylase inhibitor (HDACi) can reverse immune resistance by upregulating the expression of genes pertinent to antigen processing and presentation pathways (including B2M) in melanoma cell lines (41). Here, B2M is linked to melanoma.